Denosumab vs risedronate in glucocorticoid-induced osteoporosis: Final results of a 24-month randomized, double-blind, double-dummy trial
Arthritis & Rheumatology Mar 06, 2019
Saag KG, et al. - In this 24-month randomized, double-blind, double-dummy trial, researchers analyzed 795 subjects of ≥18 years of age receiving ≥7.5 mg daily prednisone or equivalent for <3 months (glucocorticoid-initiating) or ≥3 months (glucocorticoid-continuing) before the screening to compare the efficacy of denosumab vs risedronate in osteoporosis (glucocorticoid-induced). Investigators observed the superiority of denosumab to risedronate in increase in lumbar spine and total hip BMD among glucocorticoid-initiating subjects ie, 24-month lumbar spine: 6.2% vs 1.7%; 24-month total hip: 3.1% vs 0.0% whereas glucocorticoid-continuing subjects ie, 24-month lumbar spine: 6.4% vs 3.2% and 24-month total hip: 2.9% vs 0.5%. They observed comparable adverse effects, serious adverse events including infections, and fractures between the treatment groups.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries